- CheckMate 227 Reveals Tumour Mutational Burden as an Important and Independent Biomarker in Advanced NSCLC
- FDA Approves Nivolumab/Ipilimumab Combination for Intermediate or Poor-Risk Advanced RCC
- ESMO Immuno-Oncology Congress 2018: Abstracts
- FDA Finalises Guidances to Accelerate the Development of Reliable, Beneficial NGS-Based Tests
- EMA to Review Risk of Dosing Errors with Methotrexate
- ELCC 2018 News: New Data Support First-Line Osimertinib in Patients with NSCLC and Sensitising EGFR Mutation
Thomas R Malek
Professor and Vice-Chair
Department of Microbiology and Immunology, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, US
Department of Microbiology and Immunology, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, US
Authored articles:
Oncology & Hematology Review (US)
Citation override:
Oncology & Hematology Review, 2014;10(2):157–63